ALNYLAM PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK: 0001178670
Period of Report: 2021-08-13

Reporting Person: MARAGANORE JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-13	Common Stock	M	33979	$7.1	Acquired	248744	Direct
2021-08-13	Common Stock	S	2441	$198.02	Disposed	246303	Direct
2021-08-13	Common Stock	S	4160	$198.93	Disposed	242143	Direct
2021-08-13	Common Stock	S	23336	$199.92	Disposed	218807	Direct
2021-08-13	Common Stock	S	3828	$200.84	Disposed	214979	Direct
2021-08-13	Common Stock	S	214	$201.55	Disposed	214765	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-13	Stock Option (right to buy)	$7.1	M	33979	Disposed	2021-11-30	Common Stock (33979)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3133	Indirect

Footnotes

F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021.

F2: Sale prices ranged from $197.44 to $198.44.

F3: Sale prices ranged from $198.45 to $199.44.

F4: Sale prices ranged from $199.46 to $200.45.

F5: Sale prices ranged from $200.48 to $201.43.

F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.